Monday, January 10, 2011

Matrixx Initiatives, Inc. v. Siracusano (The Zicam nasal spray case.)

Matrixx Initiatives, Inc. v. Siracusano : SCOTUSblog:

Issue: Whether a plaintiff can state a claim under 10(b) of the Securities Exchange Act and SEC Rule 10b-5 based on a pharmaceutical company’s nondisclosure of “adverse event” reports even though the reports are not alleged to be statistically significant.
My predicition, the Court will rule for the defendant and find they are not required to disclose. The adverse events the company didn't report were incidences of Zicam nasal spray users losing their sense of smell
Related Posts Plugin for WordPress, Blogger...